Notice2021-17692

Foreign-Trade Zone (FTZ) 43-Battle Creek, Michigan; Notification of Proposed Production Activity; Pfizer, Inc. (mRNA COVID-19 Vaccine); Kalamazoo, Michigan

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
August 18, 2021

Issuing agencies

Commerce DepartmentForeign-Trade Zones Board

Full Text

<html>
<head>
<title>Federal Register, Volume 86 Issue 157 (Wednesday, August 18, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 157 (Wednesday, August 18, 2021)]
[Notices]
[Pages 46177-46178]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-17692]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-58-2021]


Foreign-Trade Zone (FTZ) 43--Battle Creek, Michigan; Notification 
of Proposed Production Activity; Pfizer, Inc. (mRNA COVID-19 Vaccine); 
Kalamazoo, Michigan

    Pfizer, Inc. (Pfizer) submitted a notification of proposed 
production activity to the FTZ Board for its facilities in Kalamazoo, 
Michigan. The notification conforming to the requirements of the 
regulations of the FTZ Board (15 CFR 400.22) was received on August 6, 
2021.
    Pfizer already has authority to produce pharmaceutical, consumer 
healthcare and animal healthcare products within Subzone 43E. The 
current request would add a finished product and a foreign-status 
material/component to the scope of authority. Pursuant to 15 CFR 
400.14(b), additional FTZ authority would be limited to the specific 
foreign-status material/component and specific finished product 
described in the submitted notification (as described below) and 
subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt Pfizer from customs 
duty payments on the foreign-status material/component used in export 
production. On its domestic sales, for the foreign-status material/
component noted below and in the existing scope of authority, Pfizer 
would be able to choose the duty rate during customs entry procedures 
that applies to the mRNA COVID-19 vaccine (duty-free). Pfizer would be 
able to avoid duty on foreign-status components which become scrap/
waste. Customs duties also could possibly be deferred or reduced on 
foreign-status production equipment.
    The proposed foreign-status material/component is mRNA bulk drug 
substance (duty rate--6.5%). The company currently intends to ship mRNA 
bulk drug substance produced at its facility in Andover, Massachusetts 
(Subzone 27R) to its Kalamazoo facilities for further processing.
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
<a href="/cdn-cgi/l/email-protection#4c2a38360c383e2d2829622b233a"><span class="__cf_email__" data-cfemail="92f4e6e8d2e6e0f3f6f7bcf5fde4">[email&#160;protected]</span></a>. The closing period for their receipt is September 27, 
2021.
    A copy of the notification will be available for public inspection 
in the ``Reading Room'' section of the Board's website, which is 
accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.

[[Page 46178]]

    For further information, contact Diane Finver at 
<a href="/cdn-cgi/l/email-protection#32765b535c571c745b5c4457407246405356571c555d44"><span class="__cf_email__" data-cfemail="8fcbe6eee1eaa1c9e6e1f9eafdcffbfdeeebeaa1e8e0f9">[email&#160;protected]</span></a>.

    Dated: August 12, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-17692 Filed 8-17-21; 8:45 am]
BILLING CODE 3510-DS-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on August 18, 2021.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.